Click on a filter below to refine your search. Remove a filter to broaden your search.
SARS-CoV-2 targets plaque macrophages, and its entry is increased in cholesterol-loaded primary macrophages.
The risk for death remains significantly elevated in the third year, as is risk for incident postacute sequelae of COVID-19.
No difference was seen for fluvoxamine or placebo in composite outcome of hospitalization, urgent care visit, emergency department visit and death.
Reduced risks for hospitalization and death were observed for mainly vaccinated outpatients aged 50 years or older with COVID-19.
Reduced mortality was seen among those receiving no or low-flow oxygen, but no benefit was seen for those who were ventilated.
An updated review of the evidence shows a small reduction in risk for SARS-CoV-2 infection with mask use versus no mask use.
59% of individuals had organ impairment at one year; breathlessness, cognitive dysfunction and poor HRQoL also were common.
The risks were associated with COVID-19 severity.
Rebound is common in untreated outpatients, but a combination of symptom and viral rebound occurs rarely.
Furthermore, patients randomly assigned to the neuroplasticity program saw significant gains in energy.